<DOC>
	<DOCNO>NCT02609503</DOCNO>
	<brief_summary>This study do evaluate efficacy Pembrolizumab , concomitant follow standard care definitive radiation , locally advance squamous cell carcinoma head neck patient good candidate Cisplatin .</brief_summary>
	<brief_title>Pembrolizumab + Radiation Locally Adv SCC Head Neck ( SCCHN ) Not Eligible Cisplatin</brief_title>
	<detailed_description>This open label , phase II trial enroll 29 subject order evaluate efficacy Pembrolizumab , concomitant follow standard care definitive radiation locally advance squamous cell carcinoma head neck patient good candidate Cisplatin . Objectives include estimate progression free survival overall survival , response rate , safety toxicity , quality life patient . Correlative study , base serial blood collection tumor sample , may do separate protocol base availability archival diagnostic tissue .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Be willing able provide write informed consent/assent trial Be great equal 18 year age Eastern Cooperative Oncology Group ( ECOG ) Performance Status less equal 1 Histologically cytologically confirm stage IIIIV ( nonmetastatic ) squamous cell carcinoma head neck define American Joint Committee Cancer . Nasopharyngeal cancer patient exclude . Ineligible high dose cisplatin therapy ; reason ineligibility must define . Demonstrate adequate organ function . All screen lab perform within 14 day treatment initiation . No prior curative attempt cancer ( i.e. , surgery , radiation and/or ) . Female patient childbearing potential negative urine serum pregnancy within 72 hour prior receive first dose study medication . Serum pregnancy test may require . Female patient childbearing potential willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication . Male patient agree use adequate method contraception start first dose study therapy 120 day last dose study therapy . As determined enrol physician protocol designee , ability patient understand comply study procedure entire length study . Consent use residual material biopsy ( archival tissue ) serial blood draw require enrollment . If currently participate participate study investigational agent use investigational device within 4 week first dose treatment . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . Has prior monoclonal antibody within 4 week prior study Day 1 recover adverse event due agent administer 4 week earlier Had prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover adverse event due previously administer agent . Has know additional malignancy metastatic , progress require active treatment . Has active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease even resolve ; patient vitiligo resolve childhood asthma/atropy would exception rule . Has clinical radiologic evidence interstitial lung disease active , noninfectious pneumonitis Has active infection require systemic therapy . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere patient 's participation full duration trial , best interest patient participate , opinion treat investigator . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . Has inadequate home environment social support safely complete trial procedure . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . Has receive prior therapy antiprogrammed cell death ( PD1 ) , antiPDL1 , antiPDL1 , antiCD137 , antiCytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody . Has know history Human Immunodeficiency Virus ( HIV ) HIV 1/2 antibody ) Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ) e.g. , HCV RNA [ qualitative ] detect ) . Has receive live vaccine within 30 day prior first dose trial treatment . Has history ( noninfectious ) pneumonitis require steroid current pneumonitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>